← Eichor
Study identifier: NCT07100782 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain

Condition: Endometriosis · Pelvic Pain  ·  Sponsor: University of Michigan

PhasePhase 3
Planned participants130
Who can joinFemale, 18 Years to 49 Years
Healthy volunteersNo

About this study

The purpose of this study is to better understand how hormone suppression with Relugolix Combination-Therapy (CT) affects pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis associated pelvic pain.

This description comes directly from the study's public registry record.

Talk to the study team

Kathy Scott  ·  734-998-7022  ·  jrsj@med.umich.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of MichiganAnn Arbor, Michigan, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07100782